Related Experiment Video
Updated: Jan 30, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?
Rosalía I Cordo Russo1, María F Chervo2, Santiago Madera2
1Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología y Medicina Experimental (IBYME), CONICET, Vuelta de Obligado 2490, C1428ADN, Buenos Aires, Argentina. rcordorusso@gmail.com.
Abstract:
Membrane overexpression of ErbB-2 (MErbB-2), a member of the ErbB family of receptor tyrosine kinases, occurs in 15-20% of breast cancers (BC) and constitutes a therapeutic target in this BC subtype (ErbB-2-positive). Although MErbB-2-targeted therapies have significantly improved patients' clinical outcome, resistance to available drugs is still a major issue in the clinic. Lack of accurate biomarkers for predicting responses to anti-ErbB-2 drugs at the time of diagnosis is also an important unresolved issue. Hence, a better understanding of the ErbB-2 signaling pathway constitutes a critical task in the battle against BC. In its canonical mechanism of action, MErbB-2 activates downstream signaling pathways, which transduce its proliferative effects in BC. The dogma of ErbB-2 mechanism of action has been challenged by the demonstration that MErbB-2 migrates to the nucleus, where it acts as a transcriptional regulator. Accumulating findings demonstrate that nuclear ErbB-2 (NErbB-2) is involved in BC growth and metastasis. Emerging evidence also reveal a role of NErbB-2 in the response to available anti-MErbB-2 agents. Here, we will review NErbB-2 function in BC and will particularly discuss the role of NErbB-2 as a novel target for therapy in ErbB-2-positive BC.
Insights
Nuclear ErbB-2 (NErbB-2) plays a key role in breast cancer (BC) growth and metastasis. Targeting NErbB-2 offers a promising new therapeutic strategy for ErbB-2-positive breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Membrane ErbB-2 (MErbB-2) overexpression occurs in 15-20% of breast cancers (BC), targeting it improves outcomes.
- Resistance to MErbB-2 targeted therapies and lack of predictive biomarkers remain significant clinical challenges.
- Understanding the ErbB-2 signaling pathway is critical for advancing BC treatment.
Purpose of the Study:
- To review the function of nuclear ErbB-2 (NErbB-2) in breast cancer.
- To discuss the emerging role of NErbB-2 in BC growth, metastasis, and therapeutic response.
- To highlight NErbB-2 as a potential novel therapeutic target for ErbB-2-positive BC.
Main Methods:
- Literature review of studies investigating ErbB-2 signaling.
- Analysis of research on MErbB-2 canonical pathway and NErbB-2 functions.
- Synthesis of evidence regarding NErbB-2's role in BC progression and treatment response.
Main Results:
- MErbB-2 can translocate to the nucleus, acting as a transcriptional regulator (NErbB-2).
- NErbB-2 is implicated in BC growth and metastasis.
- Emerging evidence suggests NErbB-2 influences response to anti-MErbB-2 therapies.
Conclusions:
- The canonical understanding of MErbB-2 action is evolving with the discovery of NErbB-2.
- NErbB-2 represents a significant factor in BC pathogenesis.
- Targeting NErbB-2 may offer a novel therapeutic avenue for ErbB-2-positive breast cancer.
More Related Videos
Related Concept Videos
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
2° Amines to N-Nitrosamines: Reaction with NaNO2
SN2 Reaction: Kinetics
In a chemical reaction, a relationship exists between the concentration of reactants and the rate at which the reaction proceeds. The study to measure this relationship is known as the kinetics of a chemical reaction. Kinetic studies are used to deduce the rate law of a chemical reaction, which provides information about the species involved during the transition state of the rate-determining step. Thus, kinetic studies help to derive the mechanism of a...
SN2 Reaction: Mechanism
The presence of the more electronegative halogen in the substrate creates a polarized carbon-halide bond. The halide pulls the electron cloud generating an electrophilic center at the carbon atom. Thus, the carbon atom carries a partial positive charge while the halide has a...
SN2 Reaction: Transition State
When the nucleophile approaches the electrophilic carbon with its lone pairs, the halide acts as a leaving group and moves away with the electron-pair bonded to the carbon. Dotted partial bonds represent the bonds being formed or broken...
SN2 Reaction: Stereochemistry
If the substrate is an achiral molecule at the α-carbon, the inversion of configuration is not...

